« Previous
Next »
The Journal of Pediatrics
Volume 153, Issue 4
, Pages
547-553.e3
, October 2008
Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
To access this article, please choose from the options below
Supported by the sanofi-aventis US Group. Chase and White have served on the sanofi-aventis US Medical Advisory Board. Arslanian has received research grant support from and has served on the sanofi-aventis US Advisory Board. Tamborlane has served on the sanofi-aventis US and Novo Nordisk Advisory Boards. The authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
PII: S0022-3476(08)00369-7
doi: 10.1016/j.jpeds.2008.04.063
© 2008 Mosby, Inc. All rights reserved.
« Previous
Next »
The Journal of Pediatrics
Volume 153, Issue 4
, Pages
547-553.e3
, October 2008
